

Adagrasib in Non-Small-Cell Lung Cancer

Siddharam Lavate¹, Abhay Gundre², Rohit Gaikwad³, Riushikesh Sarde⁴

B-Pharm Students, Department of Pharmacology^{1,2,3}

Assistant Professor, Department of Pharmaceutics⁴

Latur College of Pharmacy, Latur, Maharashtra, India

Abstract: A terse, transition-essence and protection-free conflation of adagrasib (MRTX849), a new KRASG12C asset medicine lately approved by the FDA, is reported. Preface of two chiral structure blocks to the tetrahydropyridopyrimidine core was fulfilled via two successional SNAr reactions. To estimate the safety and efficacy of the new KRAS-targeting agents, sotorasib and adagrasib, in treating KRAS G12C mutated non-small cell lung cancer (NSCLC). Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby precluding downstream signalling without affecting wild-type KRAS protein. In December 2022, adagrasib entered its first blessing in the USA for the treatment of grown-ups with KRAS G12C-shifted locally advanced or metastatic NSCLC (as determined by an FDA approved test) who have entered ≥ 1 previous systemic remedy. Cases with advanced KRASG12C-mutant solid excrescences were treated with adagrasib 150 mg orally formerly daily, 300 mg formerly daily, 600 mg formerly daily, 1,200 mg formerly daily, or 600 mg orally twice a day using an accelerated titration design, which transitioned to a modified toxin probability interval design when a predefined degree of toxin was observed or target adagrasib exposure was achieved. Safety, pharmacokinetics, and clinical exertion were estimated. Adagrasib is an orally bioavailable, largely picky, small-patch, unrecoverable covalent asset of KRAS G12C & it was approved by the US FDA on December 12, 2022, for cases with excrescences harboring the KRAS G12C & mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, conflation, lozenge and administration, medium of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described. Adagrasib, vended under the brand name Krazati, is an anticancer drug used to treat non-small cell lung cancer. Adagrasib is an asset of the RAS GTPase family. FDA Approves Adagrasib for Locally Advanced or Metastatic KRAS G12C NSCLC. This review details the preclinical and clinical data for adagrasib in the treatment of non-small-cell lung cancer. We also outline practical clinical administration guidelines for this novel remedy, including operation of venom.

Keywords: KRAS; NSCLC; drug resistance; immunotherapy; lung cancer; targeted therapy

REFERENCES

- [1]. Christensen JG, Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue JY, Gatto S, Fernandez-Banet J, Pavlicek A, Velastegui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P: The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. *Cancer Discov.* 2019 Oct 28. Pii: 2159-8290.CD-19-1167. Doi: 10.1158/2159-8290.CD-19-1167. [Article]
- [2]. Ou SI, Janne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP: First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1). *J Clin Oncol.* 2022 Aug 10;40(23):2530-2538. Doi: 10.1200/JCO.21.02752. Epub 2022 Feb 15. [Article]
- [3]. Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI: Adagrasib in Non-Small-Cell Lung Cancer Harboring a

- KRAS(G12C) Mutation. *N Engl J Med.* 2022 Jul 14;387(2):120-131. Doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3. [Article]
- [4]. Romero D: Two new agents target KRAS G12C. *Nat Rev Clin Oncol.* 2020 Jan;17(1):6. Doi: 10.1038/s41571-019-0304-3. [Article]
- [5]. Brazel D, Arter Z, Nagasaka M: A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. *Lung Cancer (Auckl).* 2022 Nov 10;13:75-80. Doi: 10.2147/LCCT.S383662. eCollection 2022. [Article]
- [6]. Tian H, Yang Z, He J: Adagrasib: A landmark in the KRAS(G12C)-mutated NSCLC. *MedComm (2020).* 2022 Nov 25;3(4):e190. Doi: 10.1002/mco2.190. eCollection 2022 Dec.
- [7]. Cancer Network: New Drug Application for Adagrasib Accepted by FDA for KRAS G12C+ NSCLC [Link]
- [8]. FDA Approved Drug Products: KRAZATI (adagrasib) tablets for oral use [Link]
- [9]. PR NewsWire: Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation [Link]
- [10]. Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. *Acta Pharm Sin B* 2019;9:871-879
- [11]. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. *JCI Insight* 2018;3(15):e120858-e120858.
- [12]. Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type. *N Engl J Med* 2021;384:185-187.
- [13]. Salem M, El-Refai S, Sha W, et al. Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. In: *Proceedings and Abstracts of the 2021 Annual Meeting of the European Society for Medical Oncology, September 16–21, 2021. Lugano, Switzerland: European Society for Medical Oncology, 2021.*
- [14]. SI, Jänne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSAL-1). *J Clin Oncol* 2022 February 15 (Epub ahead of print).
- [15]. Spira AI, Tu H, Aggarwal S, et al. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. *Lung Cancer* 2021;159:1-9.
- [16]. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. *Cancer Discov* 2020;10:54-71.
- [17]. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. *Science* 2016;351:604-608. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. *N Engl J Med.* 2022; 387(2): 120-131.
- [18]. Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. *Cancer Discov.* 2020; 10(1): 54-71.
- [19]. Adagrasib in non-small-cell lung cancer. *N Engl J Med.* 2022;387(13):1238-1239.
- [20]. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature.* 2019; 575(7781): 217-223.
- [21]. Briere DM, Li S, Calinisan A, et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. *Mol Cancer Ther.* 2021; 20(6): 975-985. [PMC free article]
- [22]. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-249.
- [23]. World Cancer Research Fund International. Lung cancer statistics. Accessed August 9, 2023. <https://www.wcrf.org/cancer-trends/lung-cancer-statistics/>

- [24]. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. *Transl Lung Cancer Res.* 2016;5(3):288-300
- [25]. American Cancer Society. Cancer facts and figures 2023. Published 2023. Accessed August 9, 2023. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf>
- [26]. Yanagawa J, Riely GJ. Management of patients with resectable and metastatic non–small cell lung cancer. *J Natl Compr Canc Netw.* 2022;20(5.5):1-5.